Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The stx1 virulence gene DNA encodes Shiga toxin 1, a potent AB5-type exotoxin primarily produced by Shiga toxin-producing Escherichia coli (STEC) and Shigella dysenteriae (StatPearls, 2023). This gene is typically carried on lambdoid prophages integrated into the bacterial chromosome, and its expression is often regulated by the bacterial SOS response system (NCBI, 2023). While the DNA sequence itself is a critical diagnostic biomarker used in clinical and food microbiology to identify pathogenic strains via PCR, it is not a direct therapeutic target for conventional drugs (CDC, 2023). The protein product of this gene consists of an enzymatic A subunit and five B subunits that facilitate entry into host cells by binding to globotriaosylceramide (Gb3) receptors (UniProt, 2024). Once inside the cytoplasm, the A subunit inactivates the 60S ribosomal subunit, halting protein synthesis and leading to cell death, which can manifest clinically as hemorrhagic colitis or life-threatening hemolytic uremic syndrome (PubMed, 1988). Therapeutic challenges include the fact that certain antibiotics can trigger the SOS response, paradoxically increasing stx1 gene expression and toxin release (Mayo Clinic, 2023).
The stx1 gene encodes the Shiga toxin 1 protein, which functions as an N-glycosidase that removes a specific adenine residue from the 28S ribosomal RNA of the 60S subunit, thereby inhibiting host cell protein synthesis (Endo et al., 1988; StatPearls, 2023).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shiga toxin 1 gene (stx1).